Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 2, 2020, covering material events occurring on September 1, 2020. Jaguar Health, Inc. (the "Company") is an emerging growth company incorporated in Delaware. The filing details significant capital structure changes involving the exchange of preferred stock, amendments to existing debt, and the settlement of consulting obligations through equity issuance.
Key Financial Metrics and Capital Structure Changes
The filing does not provide standard financial performance metrics such as revenue, net income, operating cash flow, or liquidity ratios. Instead, it reports on specific balance sheet and capitalization adjustments:
- Debt Obligation: A secured promissory note with Chicago Venture Partners, L.P. (CVP) had an original principal of $2,296,926.16. Under a new amendment, the outstanding balance increased by 5%.
- Preferred Stock Exchange: 5,524,926 shares of Series A Convertible Participating Preferred Stock held by Iliad Research and Trading, L.P. were exchanged for 842,500 shares of Series C Perpetual Preferred Stock and 842,500 shares of Series D Perpetual Preferred Stock.
- Equity Issuance: 2,289,474 shares of common stock were issued to Sagard Capital Partners to settle outstanding consulting fees.
Material Changes and Agreements
The Company entered into three definitive agreements on September 1, 2020:
- Exchange Agreement: Converted Series A Preferred Stock into Series C and Series D Perpetual Preferred Stock. Both new series rank pari passu and senior to common stock regarding dividends and liquidation.
- Debt Amendment (Global Amendment):
- Extended the maturity date of the CVP note to December 31, 2021.
- Increased the principal balance by 5% as consideration for the extension.
- Imposed a requirement to repay $50,000 in principal plus accrued interest by September 30, 2021. Failure to do so triggers a $750,000 penalty increase to the note balance.
- Added restrictive covenants prohibiting equity issuance that restricts future financing without CVP consent and prohibiting principal repayment while CVP holds Series D Preferred Stock.
- Established an automatic month-to-month extension mechanism until December 31, 2024, if the note is not repaid by the maturity date, subject to a 7.5% monthly extension fee on the outstanding balance.
- Stock Plan Agreement: Issued common stock to Sagard Capital Partners to satisfy all amounts owed under a Management Services Agreement (annual fee of $450,000). The shares are subject to a three-month lock-up, followed by a 50% trading restriction until the six-month anniversary.
Terms of New Preferred Stock Series
The filing details the rights associated with the newly designated Series C and Series D Preferred Stock:
| Feature | Series C Preferred Stock | Series D Preferred Stock |
|---|---|---|
| Shares Issued | 842,500 | 842,500 |
| Original Issue Price | $8.00 per share | $8.00 per share |
| Dividend Rate | 10% per annum (cumulative, non-participating) | 8% per annum (cumulative, non-participating) |
| Dividend Payment | Monthly in additional shares | Monthly in additional shares |
| Liquidation Preference | Original Issue Price per share | Original Issue Price per share |
| Voting Rights | Generally none, except for protective provisions | Generally none, except for protective provisions |
Risks and Contingencies
The Company faces significant financial risks associated with the amended debt instrument:
- Penalty Risk: Failure to pay $50,000 in principal and accrued interest by September 30, 2021, will result in an immediate $750,000 increase to the debt balance.
- Extension Fees: If the debt is not repaid by December 31, 2021, the Company is subject to a 7.5% monthly extension fee, which could rapidly increase the debt burden.
- Financing Restrictions: The Company is restricted from issuing equity that limits future financing or repaying the note principal without CVP consent, potentially limiting strategic flexibility.
- Dilution: The issuance of preferred stock with cumulative dividends payable in additional shares will lead to ongoing dilution of common stockholders.
Investor Verification Checklist
- Verify the current outstanding balance of the CVP note, including the 5% increase and any accrued interest.
- Confirm the Company's cash position and ability to meet the September 30, 2021, partial repayment requirement to avoid the $750,000 penalty.
- Review the full text of the Series C and Series D Certificates of Designation (Exhibits 3.1 and 3.2) for specific liquidation and conversion terms.
- Assess the impact of the 10% and 8% cumulative dividends on future capitalization and common stock dilution.
- Monitor the status of the registration statement for the resale of the 2,289,474 common shares issued to Sagard, which must be filed within 60 days of the agreement.